Advice

following an abbreviated submission:

eslicarbazepine acetate (Zebinix®) is accepted for restricted use within NHSScotland.

Indication under review: as adjunctive therapy in adolescents and children aged above 6 years with partial-onset seizures with or without secondary generalisation.

SMC restriction: patients with highly refractory epilepsy who have been heavily pre-treated and remain uncontrolled with existing anti-epileptic drugs.

SMC has previously accepted eslicarbazepine acetate for restricted use as adjunctive therapy in adults with partial-onset seizures with or without secondary generalisation.

Download detailed advice46KB (PDF)

Download

Medicine details

Medicine name:
eslicarbazepine acetate (Zebinix)
SMC ID:
SMC2087
Indication:
For adjunctive therapy in adolescents and children aged above 6 years with partial-onset seizures with or without secondary generalisation.
Pharmaceutical company
Eisai Ltd
BNF chapter
Central nervous system
Submission type
Abbreviated
Status
Restricted
Date advice published:
11 February 2019